WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. announced today the launch of a national print, television and online advertising campaign for the world’s first cervical cancer vaccine, GARDASIL® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]. GARDASIL was approved by the FDA on June 8 – and provisionally recommended by the Advisory Committee on Immunization Practices (ACIP) on June 29 – for girls and women aged 9-261. GARDASIL is the world’s first and only vaccine indicated for the prevention of HPV types 16- and 18-related cervical cancer, cervical pre-cancers (CIN 2/3 and AIS), vulvar pre-cancers (VIN 2/3) and vaginal pre-cancers (VaIN 2/3) and for the prevention of genital warts and low-grade cervical lesions (CIN 1) caused by HPV types 6, 11, 16 and 18. Adding to Merck’s ongoing cervical cancer and HPV education efforts, the new campaign, called One Less, encourages females who are eligible for the vaccine to begin their vaccination series and to also continue to see their doctor for regular healthcare and screening.
